Loading...

TC B

TC BIOPHARM (HOLDINGS) PLC

()

2024 6-K

Show Summary

Summary

AGM Results Summary

2 Sep '25

Annual Meeting Notice

5 Aug '25

Shareholder Meeting Update

27 May '25

General Meeting Notice

6 May '25

Nasdaq Delisting Notice

21 Mar '25

ADS Ratio Change

10 Feb '25

Special Dividend Announcement

8 Jan '25

Nasdaq Delisting Notice

8 Jan '25

Special Dividend Approved

31 Dec '24

Shareholder Meeting Results

30 Dec '24

Share Offering Agreement

17 Dec '24

Shareholder Meeting Notice

16 Dec '24

Financial Filing Update

25 Nov '24

Management Compensation Cha...

11 Oct '24

New Securities Offering

30 Aug '24

Regained Compliance

23 Aug '24

Equity Offering Completed

15 Aug '24

ADS Ratio Change

8 Aug '24

Nasdaq Compliance Update

6 Aug '24

Annual Meeting Results

29 Jul '24

AGM Update

1 Jul '24

Home Country Exemption

1 Jul '24

8-K Filing

28 Jun '24

Notice of Delisting or Fail...

29 May '24

Compliance with Minimum Sto...

20 May '24

Agreement with Existing War...

8 May '24

Acquisition

6 May '24

Acquisition of Assets

4 Apr '24

Shareholder Meeting

19 Mar '24

Equity Issuance

18 Mar '24

Departure of CEO and Compen...

12 Mar '24

Options Grant and Cancellation

6 Mar '24

Shareholder Update and Prox...

14 Feb '24

Delisting

4 Jan '24

External Links:

SEC

TC BioPharm plc has filed a 6-K report to disclose its qualification as a foreign private issuer under Nasdaq rules as of June 28, 2024, allowing it to follow Scottish governance practices instead of some Nasdaq requirements. This filing includes a confirmation from its legal counsel regarding compliance with local laws.

AI Assistant

TC BIOPHARM (HOLDINGS) PLC

2024

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.